In8Bio Inc (INAB) Stock Price, Quote & News

Company Profile

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its products include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product ca...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 600 6438

Website: in8bio.com

Address:

350 5th Avenue, Suite 5330, New York, United States

SkywalkerAR Feb. 3 at 1:25 PM

$INAB https://investors.in8bio.com/news-releases/news-release-details/in8bio-present-upcoming-investor-and-scientific-conferences

0 · Reply

IN8bio Feb. 2 at 11:07 PM

We’re building in one of the fastest growing areas of biotech $INAB

1 · Reply

SkywalkerAR Jan. 29 at 11:38 PM

$INAB

0 · Reply

WallStreetIsNotEasy Jan. 29 at 9:25 PM

$INAB I went shopping today 👊

0 · Reply

IN8bio Jan. 29 at 7:47 PM

We have come a long way, and we are not stopping until we reach Cancer Zero $INAB

0 · Reply

WallStreetIsNotEasy Jan. 29 at 4:40 PM

$INAB Adding as low as they want to drop it! They are basically saying the pipeline is worthless even though we have a private placement with some big time investors 🤔

1 · Reply

IN8bio Jan. 29 at 2:59 PM

The feeling when you get to Cancer Zero $INAB

0 · Reply

SkywalkerAR Jan. 28 at 8:33 AM

$INAB

0 · Reply

SkywalkerAR Jan. 27 at 10:04 PM

$INAB

0 · Reply

IN8bio Jan. 27 at 8:09 PM

Record survival rates prove we can beat cancer. Now let's get to Cancer Zero. $INAB

1 · Reply

IN8bio to Present at Upcoming Investor and Scientific Conferences in February

Jan 12, 2026, 8:00 AM EST - 22 days ago

IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma

Dec 19, 2025, 8:00 AM EST - 6 weeks ago

IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager

Nov 6, 2025, 4:00 PM EST - 3 months ago

IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Oct 29, 2025, 8:00 AM EDT - 3 months ago

IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site

Oct 27, 2025, 8:00 AM EDT - 3 months ago

IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications

Aug 7, 2025, 4:00 PM EDT - 6 months ago

IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Jun 9, 2025, 7:00 AM EDT - 8 months ago

IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial

Jun 2, 2025, 7:30 AM EDT - 8 months ago

IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival

May 14, 2025, 8:00 AM EDT - 9 months ago

IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025

May 12, 2025, 8:00 AM EDT - 9 months ago

IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary γδ T cell Manufacturing Generates Consistent and Robust Clinical Products

May 7, 2025, 4:00 PM EDT - 9 months ago

IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

Apr 29, 2025, 8:00 AM EDT - 10 months ago

IN8bio to Present Clinical and Preclinical Data from Gamma-Delta T Cell Platform at Upcoming Scientific Conferences

Apr 28, 2025, 8:00 AM EDT - 10 months ago

IN8bio Unveils Promising New Data from Next Generation Gamma-Delta T Cell Engager (TCE) Platform at AACR 2025

Mar 31, 2025, 8:00 AM EDT - 11 months ago

IN8bio to Present New Preclinical Data on Novel Gamma-Delta (γδ) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025

Mar 18, 2025, 8:05 AM EDT - 11 months ago

IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025

Mar 13, 2025, 4:05 PM EDT - 11 months ago

IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

Mar 3, 2025, 9:28 AM EST - 1 year ago

IN8bio Announces Advanced Gamma-Delta (γδ) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases

Feb 26, 2025, 8:00 AM EST - 1 year ago

IN8bio to Present at the TD Cowen 45th Annual Health Care Conference

Feb 24, 2025, 8:00 AM EST - 1 year ago

IN8bio to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Feb 14, 2025, 9:00 AM EST - 1 year ago

IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML

Feb 11, 2025, 8:00 AM EST - 1 year ago

IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients

Dec 10, 2024, 7:00 AM EST - 1 year ago

IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting

Nov 12, 2024, 4:26 PM EST - 1 year ago

IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Sep 4, 2024, 4:01 PM EDT - 1 year ago

IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia

Aug 29, 2024, 6:05 AM EDT - 1 year ago

IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 12, 2024, 8:05 AM EDT - 1 year ago

IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100

Jun 24, 2024, 8:00 AM EDT - 1 year ago

IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

Jun 13, 2024, 4:01 PM EDT - 1 year ago

IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100

Jun 3, 2024, 6:05 AM EDT - 1 year ago

IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting

May 24, 2024, 8:00 AM EDT - 1 year ago

IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024

May 23, 2024, 5:00 PM EDT - 1 year ago

IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting

May 14, 2024, 10:00 AM EDT - 1 year ago

IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress

May 13, 2024, 8:00 AM EDT - 1 year ago

IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024

May 9, 2024, 4:00 PM EDT - 1 year ago

IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

Apr 30, 2024, 6:05 AM EDT - 1 year ago

IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma

Apr 24, 2024, 8:00 AM EDT - 1 year ago

IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

Apr 16, 2024, 4:05 PM EDT - 1 year ago

IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

Apr 9, 2024, 4:30 PM EDT - 1 year ago

IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024

Mar 14, 2024, 4:00 PM EDT - 2 years ago

IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

Mar 5, 2024, 4:30 PM EST - 2 years ago

IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024

Feb 26, 2024, 8:00 AM EST - 2 years ago

IN8bio to Present at Upcoming Investor Conferences

Feb 14, 2024, 8:00 AM EST - 2 years ago

IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology

Jan 4, 2024, 8:00 AM EST - 2 years ago

IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals

Dec 11, 2023, 4:05 PM EST - 2 years ago

IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia

Dec 11, 2023, 9:00 AM EST - 2 years ago

IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement

Dec 7, 2023, 8:00 AM EST - 2 years ago

IN8bio Appoints Dr. Corinne Epperly to Board of Directors

Dec 5, 2023, 8:00 AM EST - 2 years ago

IN8bio to Host Investor Call at 8:30 AM ET on Tuesday, December 12 to Discuss Updated Clinical Data from Phase 1 Trial of INB-100 in Patients with Leukemia

Nov 20, 2023, 7:00 AM EST - 2 years ago

IN8bio's INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma

Nov 10, 2023, 7:00 AM EST - 2 years ago

IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual Meeting

SkywalkerAR Feb. 3 at 1:25 PM

$INAB https://investors.in8bio.com/news-releases/news-release-details/in8bio-present-upcoming-investor-and-scientific-conferences

0 · Reply

IN8bio Feb. 2 at 11:07 PM

We’re building in one of the fastest growing areas of biotech $INAB

1 · Reply

SkywalkerAR Jan. 29 at 11:38 PM

$INAB

0 · Reply

WallStreetIsNotEasy Jan. 29 at 9:25 PM

$INAB I went shopping today 👊

0 · Reply

IN8bio Jan. 29 at 7:47 PM

We have come a long way, and we are not stopping until we reach Cancer Zero $INAB

0 · Reply

WallStreetIsNotEasy Jan. 29 at 4:40 PM

$INAB Adding as low as they want to drop it! They are basically saying the pipeline is worthless even though we have a private placement with some big time investors 🤔

1 · Reply

IN8bio Jan. 29 at 2:59 PM

The feeling when you get to Cancer Zero $INAB

0 · Reply

SkywalkerAR Jan. 28 at 8:33 AM

$INAB

0 · Reply

SkywalkerAR Jan. 27 at 10:04 PM

$INAB

0 · Reply

IN8bio Jan. 27 at 8:09 PM

Record survival rates prove we can beat cancer. Now let's get to Cancer Zero. $INAB

1 · Reply

WallStreetIsNotEasy Jan. 27 at 4:37 PM

$INAB I’m buying! Got my avg in the 3’s 👍

0 · Reply

Picklerinthekitchen Jan. 24 at 2:46 AM

$INAB how can this price be in the kitchen ! One day it breaks out !

1 · Reply

WallStreetIsNotEasy Jan. 22 at 3:40 PM

$INAB more like $20+ it’s coming hold tight👊

1 · Reply

dogood Jan. 21 at 3:52 PM

$INAB isn’t this should run to $10?

1 · Reply

SkywalkerAR Jan. 20 at 10:02 PM

$INAB https://investors.in8bio.com/node/10506/html

0 · Reply

BillionerOfKing Jan. 20 at 4:33 AM

$INAB Current Stock Price: $2.58

0 · Reply

ZekeBalderdash Jan. 17 at 4:57 PM

$INAB The GBM data are interesting and certainly strong enough to proceed, but AA looks very unlikely to me. I'd expect several more years to accumulate 2 year data on at least 40 dosed subjects vs. controls. AML. They anticipate peer-reviewed publication of AML data by late '26. A conference presentation before then might tell us what we need to know. If the 100% PFS holds, that might get AA.

1 · Reply

StockScanners Jan. 17 at 8:07 AM

$INAB keep watch if this holds above 2.50

0 · Reply

Ulong Jan. 17 at 12:05 AM

$INAB IN8BIO Inc. has released a corporate presentation detailing advances in its pipeline focused on gamma-delta (γδ) T cell therapies. The update highlights ongoing clinical and preclinical programs, including the DeltEx platform for acute myeloid leukemia (AML) and glioblastoma (GBM), with ongoing patient dosing and upcoming clinical updates projected for late 2026. The presentation also outlines research into non-signaling CAR-T cells, induced pluripotent stem cell (iPSC)-derived T cells, and T cell engagers for potential applications in oncology and autoimmune diseases. Additional data on completed trials and plans for regulatory engagement with the FDA are provided. You can access the full presentation through the link below. https://investors.in8bio.com/news-events/events-presentations

0 · Reply

topstockalerts Jan. 16 at 6:00 PM

$INAB Big move developing as buyers pile in 😮. Price is moving with force. This is real momentum.

0 · Reply

WallStreetIsNotEasy Jan. 16 at 5:11 PM

$INAB She is warming up! The private placement is a BIG deal folks. I did call this if you look back at my posts 👍

0 · Reply

WallStreetIsNotEasy Jan. 12 at 5:34 PM

$INAB Got some more This is friggin ridiculous it’s easy money down here

0 · Reply

Market Cap	9.72M
Revenue (ttm)	0.00
Net Income (ttm)	-30.44M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	60,800
Avg Vol	333,868
Day's Range	N/A - N/A
Shares Out	4.93M
Stochastic %K	18%
Beta	-0.01
Analysts	Strong Sell
Price Target	$5.00